多发性骨髓瘤靶向治疗新进展
New Progress in Multiple Myeloma Targeted Therapy
DOI: 10.12677/ACM.2021.1111759, PDF,   
作者: 孙 琦, 高 大*：内蒙古医科大学附属医院，内蒙古 呼和浩特
关键词: 多发性骨髓瘤自体干细胞移植；卡非佐米；CAR-T；Multiple Myeloma Auto-HSCT； Carfilzomib； CAR-T
摘要: 多发性骨髓瘤(multiple myeloma, MM)是血液系统常见的恶性肿瘤，多见于老年人。MM的发病机制复杂，目前尚未完全阐明。近年来，MM治疗药物的研究已成为热点，新型蛋白酶体抑制剂、免疫调节剂、单克隆抗体和组蛋白去乙酰化酶抑制剂等靶向治疗药物相继问世。针对MM患者个体化、精准化的靶向治疗有利于改善治疗效果和预后。本文就MM靶向治疗药物的研究进展作一综述。
Abstract: Multiple myeloma (MM) is a common malignant tumor in the blood system, more common among the elderly. The pathogenesis of MM is pretty complex and has not been fully elucidated. In recent years, the research on drugs for MM has become a hot spot. And targeted drugs for MM, such as new type proteasome inhibitors, immunomodulators, monoclonal antibodies and histone deacetylase inhibitors have been successively come out. Individualized and accurate targeted therapy for MM is conducive to improving the efficacy and prognosis. This paper reviews the progress of targeted drugs for MM.
文章引用：孙琦, 高大. 多发性骨髓瘤靶向治疗新进展[J]. 临床医学进展, 2021, 11(11): 5144-5150. https://doi.org/10.12677/ACM.2021.1111759

参考文献

[1] Dosani, T., Covut, F., Pinto, R., Kim, B.-G., Ali, N., Beck, R., et al. (2019) Impact of Lenalidomide on Collected Hematopoietic Myeloid and Erythroid Progenitors: Peripheral Stem Cell Collection May Not Be Affected. Leukemia & Lymphoma, 60, 2199-2206. [Google Scholar] [CrossRef] [PubMed]
[2] 郭秋霞, 王吉刚, 刘彦琴, 刘景华, 张美玉, 李敏燕, 等. 来那度胺对多发性骨髓瘤患者自体移植造血干细胞采集影响[J]. 临床军医杂志, 2021, 49(1): 37-39, 43.
[3] Sonneveld, P., Goldschmidt, H., Rosiñol, L., Bladé, J., Lahuerta, J.J., Tacchetti, M.C., et al. (2013) Bortezomib-Based versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients with Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. Journal of Clinical Oncology, 31, 3279-3287. [Google Scholar] [CrossRef] 
[4] Huang, B., Tan, Y., Zhao, W.-H., Zeng, Q.-C., Li, B.-S. and Chen, R.-L. (2014) How to Determine Bortezomib-Based Regimen for Elderly Patients with Multiple Myeloma: PAD versus CBd, an Observational Study. Journal of Cancer Research and Clinical Oncology, 140, 303-309. [Google Scholar] [CrossRef] [PubMed]
[5] Kazandjian, D., Korde, N., Mailankody, S., Hill, E., Figg, W.D., Roschewski, M., et al. (2018) Remission and Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. JAMA Oncology, 4, 1781-1783. [Google Scholar] [CrossRef] [PubMed]
[6] Laubach, J.P. and P.G. (2015) Richardson, CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon. Clinical Cancer Research, 21, 2660-2662. [Google Scholar] [CrossRef] 
[7] Mateos, M., Cavo, M., Blade, J., Dimopoulos, M.A., Suzuki, K., Jakubowiak, A., et al. (2020) Overall Survival with Daratumumab, Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma (ALCYONE): A Randomised, Open-Label, Phase 3 Trial. The Lancet, 395, 132-141. [Google Scholar] [CrossRef] 
[8] Attal, M., Harousseau, J.-L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., et al. (2006) Maintenance Therapy with Thalidomide Improves Survival in Patients with Multiple Myeloma. Blood, 108, 3289-3294. [Google Scholar] [CrossRef] [PubMed]
[9] McCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Hassoun, H., Richardson, P.G., et al. (2012) Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 366, 1770-1781. [Google Scholar] [CrossRef] 
[10] Pulte, E.D., Dmytrijuk, A., Nie, L., Goldberg, K.B., McKee, A.E., Farrell, A.T., et al. (2018) FDA Approval Summary: Lenalidomide as Maintenance Therapy after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma. The Oncologist, 23, 734-739. [Google Scholar] [CrossRef] [PubMed]
[11] Dimopoulos, M.A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K.C., et al. (2019) Oral Ixazomib Maintenance Following Autologous Stem Cell Transplantation (TOURMALINE-MM3): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial. Lancet, 393, 253-264. [Google Scholar] [CrossRef] 
[12] Dimopoulos, M.A., Špička, I., Quach, H., Oriol, A., Hájek, R., Garg, M., et al. (2020) Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology, 38, 4030-4041. [Google Scholar] [CrossRef] 
[13] Alsina, M., et al. (2012) A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research, 18, 4830-4840. [Google Scholar] [CrossRef] 
[14] Siegel, D.S., Dimopoulos, M.A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., et al. (2018) Improvement in Overall Survival with Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 36, 728-734. [Google Scholar] [CrossRef] 
[15] Moreau, P., Mateos, M.-V., Berenson, J.R., Weisel, K., Lazzaro, A., Song, K., et al. (2018) Once Weekly versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Interim Analysis Results of a Randomised, Phase 3 Study. Lancet Oncology, 19, 953-964. [Google Scholar] [CrossRef] 
[16] Chari, A., Martinez-Lopez, J., Mateos, M.-V., Bladé, J., Benboubker, L., Oriol, A., et al. (2019) Daratumumab Plus Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 134, 421-431. [Google Scholar] [CrossRef] [PubMed]
[17] Dimopoulos, M.A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., et al. (2016) Carfilzomib and Dexamethasone versus Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (ENDEAVOR): A Randomised, Phase 3, Open-Label, Multicentre Study. Lancet Oncology, 17, 27-38. [Google Scholar] [CrossRef] 
[18] Bazou, D., Le, G., Boyle, A., Blum, A. and O’Gorman, P. (2020) Marizomib: A Novel Therapeutic Approach for the Treatment of Central Nervous System Myeloma. eJHaem, 1, 315-317. [Google Scholar] [CrossRef] [PubMed]
[19] Richardson, P.G., Zimmerman, T.M., Hofmeister, C.C., Talpaz, M., Chanan-Khan, A.A., et al. (2016) Phase 1 Study of Marizomib in Relapsed or Relapsed and Refractory Multiple Myeloma: NPI-0052-101 Part 1. Blood, 127, 2693-2700. [Google Scholar] [CrossRef] [PubMed]
[20] Richardson, P.G., Oriol, A., Beksac, M., Liberati, A.M., Galli, M., Schjesvold, F., et al. (2019) Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial. Lancet Oncology, 20, 781-794. [Google Scholar] [CrossRef] 
[21] Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre-Barbe, M., Lafon, I., et al. (2018) Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed Multiple Myeloma. Blood, 132, 2555-2563. [Google Scholar] [CrossRef] [PubMed]
[22] Dimopoulos, M.A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M.S., Richardson, P.G., Popa McKiver, M., Jou, Y.M., Shelat, S.G., Robbins, M., Rafferty, B. and San-Miguel, J. (2018) Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 379, 1811-1822. [Google Scholar] [CrossRef] 
[23] Dimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., et al. (2020) Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CANDOR): Results from a Randomised, Multicentre, Open-Label, Phase 3 Study. The Lancet, 396, 186-197. [Google Scholar] [CrossRef] 
[24] Attal, M., Richardson, P.G., Vincent Rajkumar, S., San-Miguel, J., Beksac, M., Spicka, I., et al. (2019) Isatuximab plus Pomalidomide and Low-Dose Dexamethasone versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. Lancet, 394, 2096-2107. [Google Scholar] [CrossRef] 
[25] Popat, R., Brown, S.R., Flanagan, L., Hall, A., Gregory, W., Kishore, B., et al. (2016) Bortezomib, Thalidomide, Dexamethasone, and Panobinostat for Patients with Relapsed Multiple Myeloma (MUK-Six): A Multicentre, Open-Label, Phase 1/2 Trial. Lancet Haematoogy, 3, e572-e580. [Google Scholar] [CrossRef] 
[26] Rosinol, L., Oriol, A., Rios, R., Sureda, A., Blanchard, M.J., Hernández, M.T., et al. (2019) Bortezomib, Lenalidomide, and Dexamethasone as Induction Therapy Prior to Autologous Transplant in Multiple Myeloma. Blood, 134, 1337-1345. [Google Scholar] [CrossRef] [PubMed]
[27] Sadelain, M., Riviere, I. and Riddell, S. (2017) Therapeutic T Cell Engineering. Nature, 545, 423-431. [Google Scholar] [CrossRef] [PubMed]
[28] Trudel, S., Lendvai, N., Popat, R., Voorhees, P.M,, Reeves, B., Libby, E.N., et al. (2018) Targeting B-cell Maturation Antigen with GSK2857916 Antibody-Drug Conjugate in Relapsed or Refractory Multiple Myeloma (BMA117159): A Dose Escalation and Expansion Phase 1 Trial. The Lancet Oncology, 19, 1641-1653. [Google Scholar] [CrossRef] 
[29] Lonial, S., Lee, H.C., Badros, A., Trudel, S., Nooka, A.K., Chari, A., et al. (2020) Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma (DREAMM-2): A Two-Arm, Randomised, Open-Label, Phase 2 Study. Lancet Oncology, 21, 207-221. [Google Scholar] [CrossRef] 
[30] Chng, W.J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., et al. (2014) IMWG Consensus on Risk Stratification in Multiple Myeloma. Leukemia, 28, 269-277. [Google Scholar] [CrossRef] [PubMed]
[31] Sonneveld, P., Schmidt-Wolf, I.G., van der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., et al. (2012) Bortezomib Induction and Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. Journal of Clinical Oncology, 30, 2946-2955. [Google Scholar] [CrossRef] 
[32] Bianchi, G., Richardson, P.G. and Anderson, K.C. (2014) Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area. Journal of Clinical Oncology, 32, 2125-2132. [Google Scholar] [CrossRef] 
[33] Nooka, A.K., Kaufman, J.L., Muppidi, S., Langston, A., Heffner, L.T., Gleason, C, et al. (2014) Consolidation and Maintenance Therapy with Lenalidomide, Bortezomib and Dexamethasone (RVD) in High-Risk Myeloma Patients. Leukemia, 28, 690-693. [Google Scholar] [CrossRef] [PubMed]

为你推荐